Sohini Das And Ruchika Chitravanshi

Stories by Sohini Das And Ruchika Chitravanshi

'Depending on the product, the pricing pressure will always be there'

'Depending on the product, the pricing pressure will always be there'

Rediff.com   3 Jun 2024

'That is a significant milestone for us and something we aspired for.'

New-Gen COVID Jabs Coming Soon...

New-Gen COVID Jabs Coming Soon...

Rediff.com   28 May 2024

India currently does not have any XBB 1.5 variant-based vaccines available.

Recharge Zones To Cool Clothing: Indian Companies' Summer Strategies

Recharge Zones To Cool Clothing: Indian Companies' Summer Strategies

Rediff.com   23 May 2024

Several firms are stepping up to help their workforce cope with soaring temperatures

Should Govt Continue Covid Vax Drive?

Should Govt Continue Covid Vax Drive?

Rediff.com   20 May 2024

India has covered enough population with vaccine and infection, but protein vaccines should remain available on payment basis for elderly and those with comorbidities.

M&M shifts to high gear with Rs 37K cr investments

M&M shifts to high gear with Rs 37K cr investments

Rediff.com   17 May 2024

Automotive (auto) major Mahindra & Mahindra (M&M), which is readying to launch nine sport utility vehicles (internal combustion engine/ICE), seven Born Electric Vehicles (BEVs), and seven light commercial vehicles by 2030, has outlined an investment of Rs 27,000 crore in its auto business between 2024-25 (FY25) and 2026-27 (FY27). Over the next three years, the company will deploy Rs 37,000 crore, including its auto business, farm business (Rs 5,000 crore), and service business (Rs 5,000 crore).

Will Raebareli Also Go The Amethi Way?

Will Raebareli Also Go The Amethi Way?

Rediff.com   16 May 2024

'Sonia did not visit this place once since she won. Who's to say they won't lose this one, too?'

Amethi Misses Rahul Vs Smriti Contest

Amethi Misses Rahul Vs Smriti Contest

Rediff.com   14 May 2024

'If the Congress loses this time, Rahul Gandhi will not look back at Amethi ever again.'

Getting future-ready: Govt may tweak IBC to factor in climate change

Getting future-ready: Govt may tweak IBC to factor in climate change

Rediff.com   7 May 2024

The government is contemplating changes to the Insolvency and Bankruptcy Code (IBC) to deal with environmental claims and liabilities of defaulting companies to make the law future-ready and meet climate action goals, sources told Business Standard. Currently, the IBC has various categories of claims and creditors, including those related to environmental liabilities.

Above-normal monsoon likely to ease food prices: FinMin

Above-normal monsoon likely to ease food prices: FinMin

Rediff.com   26 Apr 2024

With the prediction of an above normal monsoon in 2024, the government is expecting food prices to come down, the finance ministry's monthly economic report for March has said. The report, released on Thursday, said robust foreign inflows and comfortable trade deficits were expected to keep the rupee within a comfortable range. "Further easing of food prices is on the anvil as IMD (India Meteorological Department) has predicted above-normal rainfall during the monsoon season, which is likely to lead to higher production, assuming good spatial and temporal distribution of the rainfall," the monthly report, released by the Department of Economic Affairs, said.

Gut Health Key To Prevent Chronic Illnesses

Gut Health Key To Prevent Chronic Illnesses

Rediff.com   24 Apr 2024

Maintaining the balance of gut microbiota is important as an imbalance, also known as dysbiosis, can cause or aggravate different diseases, including but not limited to digestive problems such as inflammatory bowel syndrome, mental health issues like anxiety and depression and menstrual problems.

Zydus gets China nod for kidney disease drug

Zydus gets China nod for kidney disease drug

Rediff.com   24 Apr 2024

Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA). In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus. CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.

Centre in a huddle to understand impact of the Iran-Israel tensions

Centre in a huddle to understand impact of the Iran-Israel tensions

Rediff.com   16 Apr 2024

Top government officials in New Delhi have started discussions with stakeholders ranging from shipping and container companies to export promotion councils to understand the impact of the Iran-Israel tensions and plan ahead. Inter-ministerial talks are also being lined up amid the crisis situation in West Asia, sources confirmed. While the crude flows are not directly under any threat, elevated oil prices remain a concern, according to officials.

Consumption story gets a facelift as rural demand shows promise

Consumption story gets a facelift as rural demand shows promise

Rediff.com   16 Apr 2024

Consumer goods firms and auto companies are witnessing an upturn in rural demand, which had been lagging for most of FY24. Expectations of a bumper rabi crop harvest have helped turn the tide. The Reserve Bank of India's (RBI's) Monetary Policy Committee kept the repo rate unchanged last week, noting that as rural demand catches up, consumption is expected to support economic growth in 2024-25.

Nearly one in two luxury cars sold in March quarter was Mercedes Benz

Nearly one in two luxury cars sold in March quarter was Mercedes Benz

Rediff.com   12 Apr 2024

Nearly one in two luxury cars sold in India in the first three months of 2024 was a Mercedes Benz, which achieved its best ever quarter (January-March), selling 5,412 units, up 15 per cent year-on-year (Y-o-Y) from 4,697 units in the previous year.

Centre Plans To Raise Rs 7.5 Trillion...

Centre Plans To Raise Rs 7.5 Trillion...

Rediff.com   6 Apr 2024

...to fund the revenue gap. Of the gross market borrowing of Rs 14.13 trillion estimated for FY25, Rs 7.5 trillion, or 53 per cent, is planned to be borrowed in the first half.

Why Drug Prices Won't Increase This Year

Why Drug Prices Won't Increase This Year

Rediff.com   5 Apr 2024

The government has been stringent with pricing changes. Prices of 651 essential medicines came down from April 1, 2023 by 6.73 per cent with the government capping ceiling prices of these drugs.

Why Hospital Stays Are Getting Shorter

Why Hospital Stays Are Getting Shorter

Rediff.com   3 Apr 2024

'Every hospital now tracks length of stay closely.' 'More efficiency is brought into the system now.'

Bajaj Auto to pump Rs 3,000 crore into finance subsidiary

Bajaj Auto to pump Rs 3,000 crore into finance subsidiary

Rediff.com   1 Apr 2024

Bajaj Auto, India's leading two-wheeler (2W) and three-wheeler (3W) maker, is scaling up its wholly owned finance subsidiary, Bajaj Auto Credit Ltd (BACL), with an investment of more than Rs 3,000 crore planned over the next two financial years, company's managing director Rajiv Bajaj said. BACL has already started commercial operations, Bajaj recently said on the sidelines of the group's CSR identity event. According to rating agency CRISIL, BACL's operations began on January 1 after receiving its licence from the Reserve Bank of India (RBI) in August last year.

Frontline Relive Pandemic Nightmare

Frontline Relive Pandemic Nightmare

Rediff.com   1 Apr 2024

Battling the virus, enduring separation from loved ones, and working extended hours became part of the job.

Indian pharma companies bank on 'mother brands' to boost revenue growth

Indian pharma companies bank on 'mother brands' to boost revenue growth

Rediff.com   28 Mar 2024

Indian pharma companies are focussing on flagship products or mother brands under which they launch various new combinations to ensure robust revenue growth as well as therapy leadership. An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales. Sheetal Sapale, vice-president, commercial at Pharmarack, said, "Mother brands are analogous to an aggressive player who has put in a lot of effort during the prime years of life but now continues to silently nurture the brand family to collectively cross newer benchmarks of success."